The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
(Reuters) - The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
, opens new tab rare blood disorder treatment Soliris. Amgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex biological drugs. The approval comes with a black ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
(Reuters) - The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. Amgen's drug will be marketed ...
The approval comes with a black-box warning about the risk of serious infections caused by a bacteria called neisseria meningitidis. Amgen's drug will be marketed under the name Bkemv. Biosimilars ...
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen’s Bkemv, the first biosimilar to AstraZeneca’s rare blood disorder treatment Soliris. Amgen’s drug will be marketed under the ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. The U.S. Food and Drug Administration on Thursday approved a new ...
FRIDAY, May, 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab ...
Tarlatamab arrives after decades of no real treatment advances for this type of lung cancer. HealthDay News — The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...